Darunavir Ethanolate

CHEMBL1201127 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
593.7 g/mol
LogP
Phase
4

The ethanolate crystal form of darunavir, an HIV protease inhibitor used in combination antiretroviral therapy for HIV infection. Co-administration with a pharmacokinetic booster such as ritonavir or cobicistat is required for adequate drug exposure.

Peso molecular

593,7000 g/mol

TPSA

169,00 Ų

Áreas terapéuticas

Mecanismo de acción

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1.CCO

InChI

InChI=1S/C27H37N3O7S.C2H6O/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26;1-2-3/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32);3H,2H2,1H3/t22-,23-,24+,25-,26+;/m0./s1

Molecular Formula

C29H43N3O8S

HBD / HBA

4 / 10

Enlaces Rotables

12

Átomos Pesados

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The ethanolate crystal form of darunavir, an HIV protease inhibitor used in combination antiretroviral therapy for HIV infection. Co-administration with a pharmacokinetic booster such as ritonavir or cobicistat is required for adequate drug exposure.

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Yes, Darunavir Ethanolate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201127. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23725083. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.